勵晶太平洋：2024年年報.pdf

1、2Performance Overview業績概覽4Chairmans Statement主席報告7Directors Report董事會報告31Biographical Details of Directors and Senior Management董事及高級管理層 之履歷詳情38Managements Discussion and Analysis of the Groups Performance管理層對本集團業績 之討論及分析50Corporate Governance Report企業管治報告82Environmental,Social and Governance Report

2、環境、社會及管治報告113Independent Auditors Report獨立核數師報告119Consolidated Statement of Profit or Loss and Other Comprehensive Income綜合損益及其他全面 收益表121Consolidated Statement of Financial Position綜合財務狀況表123Consolidated Statement of Changes in Equity 綜合權益變動表125Consolidated Statement of Cash Flows綜合現金流量表127Notes to

3、the Consolidated Financial Statements綜合財務報表附註241Definitions釋義248Corporate Information公司資料CONTENTS目 錄2REGENT PACIFIC GROUP LIMITED 勵晶太平洋集團有限公司PERFORMANCE OVERVIEW業績概覽A summary of the financial performance and other notable events for the year ended 31 December 2024 include:A much-reduced loss attribu

4、table to shareholders of the Company of approximately US$4.48 million,which was mainly attributable to the Groups operating and R&D expenses of approximately US$4.99 million.A major milestone was achieved during the year when Wanbang Biopharmaceutical submitted the NDA to NMPA at the end of 2024,wit

5、h approval expected 12 months thereafter.In addition,Wanbang Biopharmaceutical received confirmation from NMPA on 24 March 2025 that the NDA registration dossier previously submitted has passed the first stage of the NMPA review process where the dossier has met all the regulatory requirements.NMPA

6、will now proceed to the next stage of the review process where it will undertake a technical evaluation of the data submitted in the NDA,with approval expected within 12 months from the submission date.If the NMPA grants an import licence for Senstend,US$5 million(before deduction of PRC withholding